NCT07056595Recruiting
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
Source: ClinicalTrials.gov · Last updated 9 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
: IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY trial demonstrated that in patients with CKD stages 1-4 and type 2 diabetes (T2D), the cardio- and nephroprotective effects of finerenone were independent of concomitant therapy with SGLT-2 inhibitors or GLP-1 receptor agonists. Thus, the role of finerenone in slowing CKD progression in T2D can be considered well-established. Given its albuminuria-reducing effects, finerenone is being investigated in multiple trials, including studies on non-diabetic kidney disease and IgA nephropathy, though no published results are available yet. In this trial finerenone will be used as a nephroprotective agent above standard treatment in terms of assessing adverse events and potential efficacy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 30 Jun 2025
- Start date
- 21 May 2025
- Primary completion date
- 21 May 2026
- Lead sponsor
- Botkin Hospital
- Diseases
- IgA nephropathy
- NCT number
- NCT07056595
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 21 May 2025 to the primary completion date, 21 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Kidney transplantation in medical history
- Acute myocardial infarction and/or stroke less then 3 months before including in trial;
Other illness
- Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;
Lab values
- Heart failure with ejection fraction \<40%;
- Presence ANCA in serum
- eGFR \< 20 ml/min
Other
- Ongoing immunosuppressive treatment
- Pregnancy and breastfeeding
- Uncontrolled blood pressure
Who the study is looking for
- Adults (\> 18 years) with the primary IgAN diagnosed by kidney biopsy;
- Treatment with stable doses of iRAS or/and iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;
- Blood pressure \< 140/90 mm Hg
- 24-hour urinary albumin excretion \> 300 mg
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Botkin Hospital Coordinator of this site? Confirm its status | Moscow | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.